Previous 10 | Next 10 |
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: NeoGenomics, Inc. 2020 Q4 - Results - Earnings Call Presentation
FT. MYERS, FL / ACCESSWIRE / February 25, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief F...
NeoGenomics, Inc. (NEO) Q4 2020 Earnings Conference Call February 24, 2021 08:30 AM ET Company Participants Doug VanOort - Chairman, CEO Kathryn McKenzie - CFO Rob Shovlin - President, Clinical Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy, CDO Charlie Ei...
Image source: The Motley Fool. Neogenomics Inc (NASDAQ: NEO) Q4 2020 Earnings Call Feb 24, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Neogenomics Inc (NEO) Q4 2020 Earnings Call Transcript
NeoGenomics (NEO) announced that Douglas M. VanOort, its Chairman and CEO for 12 years, will retire as CEO and transition to become the board's executive chairman on Apr.19, 2021.Mark Mallon, recently serving as CEO of Ironwood Pharmaceuticals, and a former EVP of Astra Zeneca, will beco...
NeoGenomics (NEO): Q4 Non-GAAP EPS of $0.14 beats by $0.08; GAAP EPS of $0.13 beats by $0.11.Revenue of $126M (+17.9% Y/Y) beats by $2.55M.Shares -0.4% PM.Press Release For further details see: NeoGenomics EPS beats by $0.08, beats on revenue
Fourth-Quarter 2020 Results and Highlights: Consolidated revenue increased 18% to $126 million Clinical Services revenue increased 14% to $107 million Pharma Services revenue increased 43% to $19 million Pharma Services backlog increased 60% to $209 million FT. ...
Mark Mallon named CEO effective April 2021; Douglas M. VanOort will retire as CEO and transition to executive chairman of the board of directors FT. MYERS, FL / ACCESSWIRE / February 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract re...
[[AVA]], [[BHC]], [[CLH]], [[CQP]], [[CSPR]], [[DEA]], [[ELAN]], [[ENBL]], [[ETR]], [[EV]], [[EXC]], [[FDP]], [[GCP]], [[HFC]], [[HZNP]], [[IBP]], [[IONS]], [[IRM]], [[ITRI]], [[KOP]], [[LIVN]], [[LNG]], [[LOW]], [[NEO]], [[ODP]], [[OMI]], [[OSTK]], [[PGTI]], [[PLAB]], [[PNW]], [[PSN]], [[RGE...
NeoGenomics (NASDAQ:NEO) is scheduled to announce Q4 earnings results on Wednesday, February 24th, before market open.The consensus EPS Estimate is $0.06 (-40.0% Y/Y) and the consensus Revenue Estimate is $123.45M (+15.5% Y/Y).Over the last 2 years, NEO has beaten EPS estimates 88% of the tim...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...